MRNA vs NVAX Stock Comparison: AI Score, Valuation, Performance and Upside
Moderna and Novavax are both companies whose fortunes were transformed by COVID vaccine development, but Moderna has a broader platform and stronger pipeline than Novavax. Moderna's mRNA technology is versatile across infectious diseases, oncology, and rare disease. Novavax's protein subunit COVID vaccine has had limited commercial success and depends on Sanofi partnership for its forward strategy. Moderna is a higher-quality speculative biotech; Novavax is a smaller, more distressed COVID vaccine story.
MRNA vs NVAX is the mRNA pioneer with RSV, influenza, and personalized cancer vaccine pipeline beyond COVID (Moderna) versus the protein subunit COVID vaccine company dependent on Sanofi partnership for commercial viability (Novavax) — platform breadth and pipeline diversity versus single-product COVID dependency.
NVAX holds the edge across 3 of 5 key metrics in this comparison. MRNA has delivered stronger 1-year price return (+505.27% vs +18.52%), though NVAX has the better forward P/E setup (-16.81x vs -30.13x for MRNA). On fundamentals, MRNA is growing revenue faster (2.10%), while NVAX maintains the higher operating margin (-89.61%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVAX (+35.68%) than for MRNA (-22.73%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer mRNA platform biotech with RSV, influenza, and personalized cancer vaccine pipeline providing multiple commercial product opportunities beyond COVID
- value mRNA platform speed and versatility for pandemic preparedness — a strategic asset as new infectious disease threats emerge
- want biotech speculation with meaningful pipeline optionality across infectious disease and oncology modalities on the same mRNA platform
- are comfortable with COVID revenue decline, cash burn, and pipeline execution risk across multiple Phase 3 programs
- prefer traditional protein subunit vaccine technology with Sanofi partnership providing manufacturing and distribution capabilities
- value Novavax as a highly speculative turnaround story if Sanofi's COVID/influenza combination vaccine partnership produces commercial success
- want smaller-cap biotech speculation with potential Sanofi milestone payments providing near-term cash runway
- are comfortable with very high execution risk, limited commercial track record vs Moderna/Pfizer, and structural dependence on Sanofi partnership for survival
| Metric | MRNA | NVAX |
|---|---|---|
| AI scorei | 56.5 | 24.4 |
| AI ranki | #246 | #3307 |
| Latest closei | $154.04 | $10.11 |
| 1M returni | -11.66% | +15.02% |
| 6M returni | +194.14% | +5.09% |
| 1Y returni | +505.27% | +18.52% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MRNA | NVAX |
|---|---|---|
| 1Y ago | $60.53K (+505.3%) started 2025-09-18 | $11.85K (+18.5%) started 2025-09-18 |
| 5Y ago | $3.64K (-63.6%) started 2021-09-20 | $445.53 (-95.5%) started 2021-09-20 |
| 10Y ago | $82.82K (+728.2%) started 2018-12-07 | $3.39K (-66.1%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | MRNA | NVAX |
|---|---|---|
| Market capi | $55.09B | $1.7B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -30.13 | -16.81 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 23.00 | 3.01 |
| Analyst targeti | $106.63 | $14.00 |
| Target upsidei | -22.73% | +35.68% |
| Metric | MRNA | NVAX |
|---|---|---|
| Revenue growthi | 2.10% | -76.30% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +13.43% | +37.07% |
| Operating margini | -557.93% | -89.61% |
| Profit margini | -141.43% | -59.87% |
| ROIC proxyi | -39.00% | N/A |
| Return on equityi | -39.00% | N/A |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.90 | 2.42 |
| Debt/equityi | 19.04 | N/A |
| Current ratioi | 2.29 | 2.33 |
| Quick ratioi | 2.07 | 2.23 |
Over the past year, MRNA and NVAX have moved weakly in the same direction (correlation of 0.37), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MRNA | NVAX |
|---|---|---|---|
| 1Y | Growthi | +505.27% | +18.52% |
| CAGRi | +506.01% | +18.54% | |
| Volatilityi | 192.18% | 64.62% | |
| Sharpe ratioi | 1.46 | 0.51 | |
| Sortino ratioi | 5.95 | 0.85 | |
| Max drawdowni | 34.16% | 34.87% | |
| Current drawdowni | 11.66% | 9.65% | |
| Avg drawdowni | 11.56% | 18.23% | |
| Ulcer Indexi | 14.35% | 20.52% | |
| Max daily dropi | 23.55% | 9.38% | |
| Max wkly dropi | 18.08% | 17.98% | |
| 5Y | Growthi | -63.61% | -95.54% |
| CAGRi | -18.32% | -46.37% | |
| Volatilityi | 103.99% | 104.47% | |
| Sharpe ratioi | 0.12 | -0.16 | |
| Sortino ratioi | 0.28 | -0.25 | |
| Max drawdowni | 95.08% | 98.54% | |
| Current drawdowni | 66.12% | 96.07% | |
| Avg drawdowni | 76.44% | 89.62% | |
| Ulcer Indexi | 78.10% | 91.24% | |
| Max daily dropi | 23.55% | 34.30% | |
| Max wkly dropi | 33.81% | 39.76% | |
| 10Y | Growthi | +728.17% | -66.07% |
| CAGRi | +31.21% | -10.25% | |
| Volatilityi | 96.54% | 112.26% | |
| Sharpe ratioi | 0.61 | 0.40 | |
| Sortino ratioi | 1.24 | 0.67 | |
| Max drawdowni | 95.38% | 98.82% | |
| Current drawdowni | 68.20% | 96.84% | |
| Avg drawdowni | 57.58% | 68.90% | |
| Ulcer Indexi | 65.45% | 75.47% | |
| Max daily dropi | 23.55% | 66.67% | |
| Max wkly dropi | 33.81% | 73.24% |
| Category | MRNA | NVAX |
|---|---|---|
| Company | Moderna, Inc. | Novavax, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Moderna is an mRNA biotechnology company best known for developing one of the first COVID-19 vaccines (Spikevax). Moderna's mRNA platform is its core technology — using messenger RNA to instruct cells to produce proteins that trigger immune responses. Beyond COVID, Moderna is advancing mRNA vaccines for RSV (Mresvia approved), influenza, and personalized cancer vaccines (in partnership with Merck). Moderna's pipeline spans infectious disease and oncology, betting the mRNA platform will produce multiple commercial vaccines beyond COVID. | Novavax makes protein subunit vaccines — traditional-technology vaccines that use protein nanoparticles rather than mRNA. Novavax's COVID vaccine (Nuvaxovid) was approved as a non-mRNA COVID option for individuals concerned about mRNA vaccines. Unlike Moderna, Novavax has been struggling commercially — Nuvaxovid's late approval and smaller marketing infrastructure limited market penetration. Novavax entered a partnership with Sanofi for COVID/influenza combination vaccine development. Novavax's pipeline is narrower than Moderna's. |
| Investor focus | Investors track COVID vaccine revenue (declining), RSV vaccine (Mresvia) market penetration, influenza mRNA vaccine pipeline timelines, and the personalized cancer vaccine (mRNA-4157 with Merck) clinical progress. | Investors track COVID vaccine sales, Sanofi partnership milestones and payments, and whether the Sanofi combination vaccine collaboration can provide a sustainable commercial future. |
- mRNA platform speed advantage — Moderna can design and manufacture new vaccines faster than traditional platforms, useful for pandemic response and annual strain updates
- RSV vaccine (Mresvia) is approved and commercializing in adults 60+ — adding a second commercial product beyond COVID
- Personalized cancer vaccine with Merck (mRNA-4157/V940 for melanoma) is in Phase 3 — if successful, creates an entirely new oncology modality
- Protein subunit technology provides a traditional vaccine option for mRNA-hesitant populations — a distinct positioning vs Moderna and Pfizer mRNA vaccines
- Sanofi partnership provides manufacturing capabilities and distribution relationships Novavax couldn't build independently
- COVID + influenza combination vaccine in development with Sanofi could address combination vaccine market preferences
- COVID vaccine revenue is declining rapidly — without RSV and influenza pipeline success, Moderna faces significant revenue decline as its only major commercial product shrinks
- Pfizer/BioNTech mRNA COVID vaccines compete directly; GSK and Sanofi compete in RSV; Pfizer mRNA dominates influenza mRNA pipeline
- Moderna has been burning significant cash — without revenue recovery from new products, the balance sheet will require raising capital
- Novavax's COVID commercial performance has been very weak — limited market penetration and smaller scale than Pfizer/Moderna competitors
- Cash burn is significant — Novavax has been dependent on COVID advance purchase agreements and the Sanofi partnership for revenue
- Protein subunit vaccines' advantage (mRNA-hesitancy addressable market) is narrower than mRNA's broader pandemic preparedness application
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.